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To the editor
The success of direct acting anti virals(DAA) in curing chronic hepatitis C(CHC) infection is well documented and most patients can achieve sustained virological response at week 12(SVR12) with 8-12 weeks of therapy (1) . However as DAA therapy is accessed by populations of challenged life circumstances, such as people who inject drugs(PWID), adhering to treatment for several month might be more difficult. This issue was evident in multiple presentations at the recent International Network for Hepatitis in Substance Users 2017 meeting(2).
We would therefore, in the context of treating hepatitis C for elimination as a public health threat as defined by the WHO(3) like to draw your attention to a pilot trial of 4 weeks treatment for CHC At the time of trial design there were no published results on 4 week trials and models of HCV viral kinetics predicted that 4 weeks of viral suppression might be too short to achieve cure (4).
However case reports including cases from clinical trials on DAA with premature treatment abruption have documented cure with 4 weeks of treatment or less. The very high SVR 12 rates with 8-12 weeks of therapy also indicates that a subset of "easy to treat" patient might be cured with shorter treatment. We therefore designed inclusion criteria to exclude patients with negative predictors for treatment success such as high viral load (VL), obesity , older age, significant liver fibrosis/cirrhosis and being treatment experienced(5, 6).
As DAA-backbone ledipasvir/sofosbuvir (LDV/SOF) was chosen as the most potent combination available in 2014 across genotypes. After initiation of the trial LDV/SOF+RBV was reported to be less efficient in genotype 3 patients with severe liver disease but as results in mild diseases were still acceptable the trial continued unchanged (7) . High dose RBV at 15 mg/kg were in some trials(interferon era) more favorable than fixed dose and used in the trial. Pegylated interferon 2a(INF) was chosen as the interferon option.
The study was conducted at an outreach drug treatment center targeting mainly the PWID population because this in our setting would be the main real life target populations for short treatment.
We None of the study subjects were eligible for standard of care treatment due to fibrosis (F2 or LSM>10kPa) treatment restrictions in Denmark(still valid). As of April 2015 there were 115 persons aged 18-49 years registered at the clinic. Of these 58%
were not screened mainly due to known cirrhosis or lost to follow-up. A total of 48 persons gave informed consent, 12 failed screening, 5 of these due to high viral load and the remaining due to lost to follow-up or worsening of preexisting psychiatric co-morbidity. In total 36 patients were randomized(18 in each arm) and 32 initiated therapy(16 in each arm) and constituted the intention to treat(ITT) population(please refer to CONSORT flow diagram in supp.). The baseline characteristics(ITT) is presented in table 1.
The trial stopped at the planned end date with 36 randomized subjects. Further inclusion was considered futile given the (high) cure rates observed in both arms making conclusions on the primary aim unlikely. They reported SVR 12 rates from 20-40%. Besides using DAA-only without RBV or INF, trial populations were older (mean or median age 52-58 years) and included patients with higher viral loads and slightly more advanced fibrosis (8) (9) (10) . These trials also reported that treatment failures were retreated with 12 week regimens with success and with no treatment emergent RAS (9, 10).
Generating treatment emergent resistant associated substitutions (RAS) with short course DAA treatment is an intuitive concern, neither this study nor the studies mentioned above have found RAS to be a problem in short course treatment.
The study also indicates that adherence to therapy and follow-up will be an issue and having effective ultra-short treatment options might be valuable even if this means including RBV when we expand treatment to population with ongoing transmission. Even though 4 weeks treatment should only be further investigated in patients with favorable baseline characteristics this is the majority of patients we need to treat in our setting in forthcoming years.
In conclusion we believe this study raises the question if adding RBV to a potent pan genotypic DAA is an option worth exploring further if aiming at shortening therapy to 4 weeks. Better designed and larger studies are surely needed. Future trials might also elucidate the relative importance of RBV(dose), age, liver fibrosis and viral load for an successful outcome in ultra-short treatment.
SVR 12 rate for the ITT and PP population
In the intention to treat analysis, 94% in the interferon arm and 75% in the interferon-free arm (p=0.14) achieved SVR12. One patient in the interferon arm and 3 patients in the interferon free arm droppedout/lost to follow up making SVR12 in the per protocol population 100% and 92% respectively(p=0.28). Table 1 
